The AMPLIFY study [NCT03836261] did not include patients with del (17p), so that doublet is not relevant. The study that used ...

Dr. Mary Maluccio discusses the promising next steps for 212Pb-DOTAMTATE in treating GEP-NETs, including a pivotal phase 3 ...

Specifically, in the PRRT-naive cohort, the ORR reached 60%, while 34.1% of patients showed stable disease. Combining these ...

A panelist discusses how data from the DeLLphi-304 trial position tarlatamab as a potential new standard for relapsed ...

Panelists discuss current frontline therapeutic strategies for advanced melanoma, highlighting the rationale and evolution of ...

Jaume Capdevila, MD, Vall d'Hebron Hospital, discusses the final analysis of the phase 3 COMPETE trial (NCT03049189). Data ...

A panelist discusses how proactive management of CRS and ICANS supports safe community use of DLL3-targeted therapy.

CT scan of chest, abdomen, and pelvis shows high-disease burden, including multiple mediastinal and hilar nodes, deposits in ...

The investigational oral KRAS G12D inhibitor VS-7375 (GFH375) has shown a promising early safety profile and preliminary antitumor activity in pretreated patients with advanced solid tumors harboring ...

An expert discusses how the KEYNOTE-905 trial findings established pembrolizumab as a groundbreaking perioperative immunotherapy approach for cisplatin-ineligible muscle-invasive bladder cancer, ...

Healthcare professionals adjust octreotide and lanreotide doses for effective symptom control in patients with carcinoid ...

At an interim analysis of the phase 3 LITESPARK-011 trial (NCT04586231), the oral combination of belzutifan (Welireg) plus ...